Conversely, the phase III MYSTIC trial358 and the NEPTUNE trial359 failed to demonstrate that, as first-line treatment of NSCLC, combination therapy with durvalumab or tremelimumab (an antibody blocking CTLA-4) could improve OS or PFS over standard chemotherapy. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.